The striking reduction in cardiovascular disease risk associated with icosapent ethyl (IPE) seen in the REDUCE-IT trial appears to be the work of the omega-3 fatty acid eicosapentaenoic acid (EPA), according to late-breaking trial results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.